文献速递血液净化与透析

透析患者的疫苗接种与COVID-19动态变化

Vaccination and COVID-19 Dynamics in Dialysis Patients.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-02-10

该研究采用贝叶斯多变量时空模型,分析法国终末期肾病登记系统中透析患者疫苗接种与SARS-CoV-2重症感染(需住院)的关联。结果显示,透析患者疫苗暴露的发病率比比为0.37(95%CI 0.18-0.71),同年龄一般人群疫苗接种覆盖率每提高10%的发病率比为0.50(95%CI 0.40-0.61),二者均与透析患者住院率降低独立相关。结论提示疫苗接种可能对透析患者重症COVID-19产生保护效应。

要点

  • 透析患者疫苗暴露与重症COVID-19住院风险降低独立相关,发病率比0.37(95%CI 0.18-0.71)。
  • 同年龄一般人群疫苗接种覆盖率每提高10%,透析患者住院发病率比0.50(95%CI 0.40-0.61)。
  • 尽管免疫应答改变,疫苗接种可能对透析患者重症COVID-19产生保护效应。

核心结论

  • 研究提示疫苗接种可能对透析患者重症COVID-19产生保护效应,尽管其免疫疫苗应答发生改变。

研究设计与样本

  • 采用贝叶斯多变量时空模型,估计透析患者疫苗暴露与SARS-CoV-2重症感染(需住院)的关联,并与一般人群同期发病率比较。
  • 透析患者病例来自法国终末期肾病REIN登记系统,报告时间为2020年3月11日至2021年4月29日;疫苗暴露(第一剂)来自2021年起的每周全国调查。
  • 一般人群病例来自全国 exhaustive 住院监测系统(SI-VIC数据库),疫苗接种覆盖率(第一剂)来自全国监测系统(VAC-SI数据库)。

主要发现

  • 第一波疫情期间,透析患者发病率大致与一般人群成比例。
  • 第二波疫情期间,透析患者相对发病率低于非透析患者,提示预防措施的效果。
  • 疫苗接种推广开始后,透析患者发病率低于基于第一波和第二波的预测值。
  • 将透析和非透析患者的疫苗接种覆盖率作为预测变量加入模型后,可正确拟合报告病例(预测3685例,95%CI 3552-3816,对比报告3620例)。
  • 透析患者疫苗暴露的发病率比为0.37(95%CI 0.18-0.71),同年龄一般人群疫苗接种覆盖率每提高10%的发病率比为0.50(95%CI 0.40-0.61),表明二者与透析患者住院率降低独立相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Dialysis patients have a high mortality risk after coronavirus disease 2019 (COVID-19) and an altered immunologic response to vaccines, but vaccine clinical effectiveness remains unknown in this population. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using Bayesian multivariable spatiotemporal models, we estimated the association between vaccine exposure and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severe infections (with hospital admission) in dialysis patients from simultaneous incidence in the general population. For dialysis patients, cases were reported within the French end-stage kidney disease REIN registry from March 11, 2020, to April 29, 2021, and vaccine exposure (first dose) was reported in weekly national surveys since January 2021. Cases in the general population were obtained from the national exhaustive inpatient surveillance system (SI-VIC database), and vaccination coverage (first dose) was obtained from the national surveillance system (VAC-SI database). RESULTS: During the first wave, incidence in dialysis patients was approximately proportional to the general population. However, we showed a lower relative incidence for dialysis patients during the second wave (compared with that observed in nondialysis patients), suggesting an effect of prevention measures. Moreover, from the beginning of the vaccination rollout, incidence in dialysis patients was lower compared with predictions based on the first and second waves. Adding vaccination coverages in dialysis and nondialysis patients as predictors allowed the reported cases to be fit correctly (3685 predicted cases, 95% confidence interval, 3552 to 3816, versus 3620 reported). Incidence rate ratios were 0.37 (95% confidence interval, 0.18 to 0.71) for vaccine exposure in dialysis patients and 0.50 (95% confidence interval, 0.40 to 0.61) per 10% higher in vaccination coverage in the same-age general population, meaning that vaccine exposure in dialysis patients and the general population was independently associated with lower hospitalization rate of dialysis patients. CONCLUSIONS: Our findings suggest that vaccination may yield a protective effect against severe forms of COVID-19 in dialysis patients, despite altered immunologic vaccine responses.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. El Karoui K, Hourmant M, Ayav C, et al. Vaccination and COVID-19 Dynamics in Dialysis Patients. Clin J Am Soc Nephrol. 2022. PMID: 35144970. doi:10.2215/CJN.10300721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。